Today: 16 May 2026
Browse Category

Earnings Reports 4 January 2026

Micron stock jumps 10% on Bernstein’s $330 target — what MU investors watch before Monday’s open

Micron stock jumps 10% on Bernstein’s $330 target — what MU investors watch before Monday’s open

Micron shares jumped 10.5% to $315.42 Friday, hitting $319.60 intraday after Bernstein raised its price target to $330, citing strong AI-driven demand for memory chips. The company recently reported fiscal Q1 revenue of $13.64 billion and guided Q2 revenue to $18.7 billion. The Philadelphia Semiconductor Index gained 4%. U.S. economic data resumes Monday with ISM manufacturing.
4 January 2026
···
Citigroup stock rises into 2026 as rate bets shift — what to watch before earnings

Citigroup stock rises into 2026 as rate bets shift — what to watch before earnings

Citigroup shares closed up 1.7% at $118.70 on Friday, about 3% below their 52-week high. The stock tracked gains in other major U.S. banks as Treasury yields edged higher. Investors await Citi’s Jan. 14 earnings report and fresh guidance after the bank flagged a $1.2 billion pre-tax loss from its Russian unit sale. Trading volume reached about 9.25 million shares.
4 January 2026
··
Thermo Fisher stock closes higher near 52-week high as January data, earnings loom

Thermo Fisher stock closes higher near 52-week high as January data, earnings loom

Thermo Fisher Scientific shares rose 2.25% to $592.51 Friday, closing about 3% below their 52-week high. The company will report Q4 and full-year results before the market opens on Jan. 29. Investors are watching for the ISM manufacturing report on Jan. 5 and U.S. jobs data on Jan. 9. Thermo Fisher’s $9.4 billion Clario deal is expected to close in early 2026.
4 January 2026
··
Workday stock slips to new 52-week low as investors brace for jobs data and Feb earnings

Workday stock slips to new 52-week low as investors brace for jobs data and Feb earnings

Workday shares fell 4.2% to $205.79 Friday, hitting a new 52-week low of $202.22 on heavy volume. The drop came as Treasury yields rose and investors rotated into value stocks, leaving business-software names mixed. Oracle edged higher while Accenture slid over 3%. Workday’s next earnings report is expected in late February.
4 January 2026
·····
Verizon stock dips into 2026 as yields rise — what investors watch before VZ earnings

Verizon stock dips into 2026 as yields rise — what investors watch before VZ earnings

Verizon shares closed down 0.6% at $40.52 on Friday, trailing a broader market gain as Treasury yields rose. The company will report fourth-quarter results on Jan. 30 and pay its next dividend on Feb. 2. Investors are watching upcoming U.S. jobs and inflation data for signals on interest rates. Verizon’s stock is trading near its 50-day moving average, with a 52-week range of $37.59 to $47.36.
4 January 2026
··
P&G stock slips to start 2026: what to watch before Procter & Gamble’s Jan. 22 earnings

P&G stock slips to start 2026: what to watch before Procter & Gamble’s Jan. 22 earnings

Procter & Gamble shares fell 1.06% to $141.79 Friday, extending a four-day slide and closing about 21% below their 52-week high. The company is set to report fiscal Q2 results on Jan. 22, with analysts expecting earnings of $1.87 per share on $22.3 billion in revenue. PG shares are trading near the bottom of their 52-week range. Investors will watch for updates on demand, pricing, and margins.
4 January 2026
··
Asana stock slides 5% to start 2026 — downgrade and key dates that could move ASAN next

Asana stock slides 5% to start 2026 — downgrade and key dates that could move ASAN next

Asana shares fell 5.4% to $12.96 Friday after Wall Street Zen downgraded the stock to “hold,” MarketBeat reported. The drop leaves Asana near its 52-week low, with investors watching for signs of further U.S. rate cuts after Fed officials signaled patience. The S&P 500 rose 0.2% while the Nasdaq-100 slipped 0.2%. Asana last forecast Q4 revenue of $204 million to $206 million.
4 January 2026
··
Establishment Labs (ESTA) stock drops 5.5% — what to watch before Monday’s open and JPM conference

Establishment Labs (ESTA) stock drops 5.5% — what to watch before Monday’s open and JPM conference

Establishment Labs shares fell 5.5% to $68.84 Friday, underperforming a flat Nasdaq. The company recently submitted its Motiva implants to the FDA for breast reconstruction approval. Management will present at the J.P. Morgan Healthcare Conference on Jan. 14. Establishment Labs posted a 2024 net loss of about $85 million on $166 million in revenue.
4 January 2026
··
BILL stock slides 7% to start 2026 despite KBW target raise — what to watch Monday

BILL stock slides 7% to start 2026 despite KBW target raise — what to watch Monday

BILL Holdings shares fell 7.3% to $50.56 Friday, marking one of their steepest single-day drops in weeks. Keefe, Bruyette & Woods raised its price target to $60 but maintained a “market perform” rating. The decline came as the S&P 500 rose 0.19% and the Nasdaq was flat. BILL’s next key events include a Jan. 16 finance leadership change and an earnings update expected in early February.
4 January 2026
··
JPMorgan stock closes higher to start 2026 — what investors watch before earnings

JPMorgan stock closes higher to start 2026 — what investors watch before earnings

JPMorgan shares closed up 1.0% at $325.48 on Friday, the first trading day of 2026. The bank will report fourth-quarter and full-year results on Jan. 13, with investors focused on net interest income and expense forecasts. JPMorgan trades about 1.6% below its 52-week high. A director received shares through a deferred board retainer, according to a recent Form 4 filing.
4 January 2026
··
1 … 161 162 163 164 165 … 248

Stock Market Today

  • W. R. Berkley (WRB) Shows 45.9% Undervaluation Despite Recent Price Stability
    May 15, 2026, 7:55 PM EDT. W. R. Berkley (WRB) stock has shown limited movement recently with a 1.2% gain over 7 days and a 4.2% decline year-to-date. Analysts use valuation methods like Excess Returns, which estimates intrinsic value by calculating profits above shareholder required returns. With an intrinsic value estimate of $122.79 against a current price near $66.45, the stock appears 45.9% undervalued. The insurer's steady underwriting profile and capital discipline contrast with sector concerns on insurance pricing and interest rate sensitivity. WRB currently scores 2 out of 6 on valuation metrics, highlighting potential but raising caution.

Latest articles

Accuray inks 10-year cancer tech agreement, shares in focus

Accuray inks 10-year cancer tech agreement, shares in focus

16 May 2026
Accuray and the University of Wisconsin School of Medicine and Public Health signed a 10-year research agreement focused on Accuray’s Stellar adaptive radiotherapy platform. The announcement came after market close, with Accuray shares ending down 5.2% at $0.27. The deal follows Accuray’s recent withdrawal of fiscal 2026 guidance and ongoing financial pressures.
Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

16 May 2026
Origin Materials asked shareholders to approve a plan to liquidate and dissolve the company, estimating an initial payout of $0.61 to $3.54 per share depending on asset sales and claims. Shares rose 15% to $1.43 after the filing. The company reported a 91% drop in first-quarter revenue and warned it may not survive without the wind-down. Origin cut 59% of its workforce and CEO John Bissell stepped down May 1.
NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

16 May 2026
NextNRG reported first-quarter revenue of $21.1 million, up 29% from a year earlier, but its net loss widened to $10.8 million. Cash fell to $208,048 at quarter-end, and management warned it needs immediate capital to continue operations. Shares closed at $0.2804 on Nasdaq, down nearly 6%. Total liabilities reached $34.3 million, with a stockholders’ deficit of $22 million.
HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

16 May 2026
HCW Biologics shares jumped 262% to $1.22 Friday after the company posted a $3.47 million first-quarter profit, driven by a $6.5 million licensing deal with Beijing Trimmune Biotech. The company faces a possible Nasdaq delisting and will ask shareholders to approve a reverse stock split on June 15. HCW plans to report early Phase 1 data for its alopecia drug in the first half of 2026.
Go toTop